Mechanistic Target of Rapamycin Inhibitors and Vaccine Response in Kidney Transplant Recipients

Griffith B Perkins^{1

2

3}, Matthew J Tunbridge^{1

2}, Cheng Sheng Chai², Christopher M Hope^{2

4

5}, Arthur Eng Lip Yeow^{2

6}, Tania Salehi¹, Julian Singer^{7

8}, Bree Shi^{7

8}, Makutiro G Masavuli^{2

6}, Zelalem Addis Mekonnen^{2

6}, Pablo Garcia-Valtanen^{2

6

9}, Svjetlana Kireta^{1

2}, Julie K Johnston^{1

2}, Christopher J Drogemuller^{1

2}, Beatrice Z Sim^{1

10}, Shane M Spencer^{2

11}, Benedetta C Sallustio^{2

11}, Iain Comerford¹², George Bouras^{2

13}, Daniela Weiskopf¹⁴, Alessandro Sette^{14

15}, Anupriya Aggarwal¹⁶, Vanessa Milogiannakis¹⁶, Anouschka Akerman¹⁶, Stuart Turville¹⁶, Plinio R Hurtado^{1

2}, Tracey Ying^{7

8}, Pravin Hissaria^{2

3

17}, Simon C Barry^{2

4

5}, Steven J Chadban^{7

8}, Branka Grubor-Bauk^{2

6}, P Toby Coates^{1

2}

Affiliations

¹ Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
² Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
³ Immunology Directorate, SA Pathology, Adelaide, South Australia, Australia.
⁴ Molecular Immunology, Robinson Research Institute, University of Adelaide, Adelaide, South Australia, Australia.
⁵ Paediatric Medicine, Women's and Children's Hospital, North Adelaide, South Australia, Australia.
⁶ Viral Immunology Group, Basil Hetzel Institute for Translational Health Research, University of Adelaide, Woodville, South Australia, Australia.
⁷ Kidney Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
⁸ Kidney Node, Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia.
⁹ Instituto de Investigacion, Desarrollo e Innovacion en Biotecnologia Sanitaria, Universidad Miguel Hernandez, Elche, Spain.
¹⁰ National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
¹¹ Clinical Pharmacology Research Group, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville, South Australia, Australia.
¹² Chemokine Biology Laboratory, School of Biological Sciences, University of Adelaide, Adelaide, South Australia, Australia.
¹³ Otolaryngology, Head and Neck Surgery Group, Basil Hetzel Institute for Translational Health Research, University of Adelaide, Woodville, South Australia, Australia.
¹⁴ Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California.
¹⁵ Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego (UCSD), La Jolla, California.
¹⁶ Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
¹⁷ Department of Immunology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

PMID: 40403135
DOI: 10.1681/ASN.0000000716

Mechanistic Target of Rapamycin Inhibitors and Vaccine Response in Kidney Transplant Recipients

Griffith B Perkins et al. J Am Soc Nephrol. 2025.

. 2025 May 22.

doi: 10.1681/ASN.0000000716. Online ahead of print.

Authors

Affiliations

¹ Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
² Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
³ Immunology Directorate, SA Pathology, Adelaide, South Australia, Australia.
⁴ Molecular Immunology, Robinson Research Institute, University of Adelaide, Adelaide, South Australia, Australia.
⁵ Paediatric Medicine, Women's and Children's Hospital, North Adelaide, South Australia, Australia.
⁶ Viral Immunology Group, Basil Hetzel Institute for Translational Health Research, University of Adelaide, Woodville, South Australia, Australia.
⁷ Kidney Centre, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
⁸ Kidney Node, Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia.
⁹ Instituto de Investigacion, Desarrollo e Innovacion en Biotecnologia Sanitaria, Universidad Miguel Hernandez, Elche, Spain.
¹⁰ National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
¹¹ Clinical Pharmacology Research Group, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Woodville, South Australia, Australia.
¹² Chemokine Biology Laboratory, School of Biological Sciences, University of Adelaide, Adelaide, South Australia, Australia.
¹³ Otolaryngology, Head and Neck Surgery Group, Basil Hetzel Institute for Translational Health Research, University of Adelaide, Woodville, South Australia, Australia.
¹⁴ Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California.
¹⁵ Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego (UCSD), La Jolla, California.
¹⁶ Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
¹⁷ Department of Immunology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.

PMID: 40403135
DOI: 10.1681/ASN.0000000716

No abstract available

Keywords: COVID-19; clinical trial; immunology; immunosuppression; kidney transplantation; randomized controlled trials.

PubMed Disclaimer

References

1. Phanish M, Ster IC, Ghazanfar A, et al. Systematic review and meta-analysis of COVID-19 and kidney transplant recipients, the South West London Kidney Transplant Network experience. Kidney Int Rep. 2021;6(3):574–585. doi: 10.1016/j.ekir.2020.12.013 - DOI
1. Cochran W, Shah P, Barker L, et al. COVID-19 clinical outcomes in solid organ transplant recipients during the Omicron surge. Transplantation. 2022;106(7):e346–e347. doi: 10.1097/TP.0000000000004162 - DOI
1. Callaghan CJ, Mumford L, Curtis RM, et al.; the NHSBT Organ and Tissue Donation and Transplantation Clinical Team. Real-world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against SARS-CoV-2 in solid organ and islet transplant recipients. Transplantation. 2022;106(3):436–446. doi: 10.1097/TP.0000000000004059 - DOI
1. Charmetant X, Espi M, Benotmane I, et al. Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients. Sci Transl Med. 2022;14(636):eabl6141. doi: 10.1126/scitranslmed.abl6141 - DOI
1. Benotmane I, Gautier G, Perrin P, et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA. 2021;326(11):1063–1065. doi: 10.1001/jama.2021.12339 - DOI

Grants and funding

LinkOut - more resources

Full Text Sources
- Wolters Kluwer

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Mechanistic Target of Rapamycin Inhibitors and Vaccine Response in Kidney Transplant Recipients

Affiliations

Mechanistic Target of Rapamycin Inhibitors and Vaccine Response in Kidney Transplant Recipients

Authors

Affiliations

References

Grants and funding

LinkOut - more resources

Full Text Sources